Novartis AG - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US66987V1098

SecurityNVS / Novartis AG - Depositary Receipt (Common Stock)
InstitutionAtlantic Trust, LLC
Latest Disclosed Ownership550 shares
Latest Disclosed Value $ 84,013
Atlantic Trust, LLC reports 20.98% decrease in ownership of NVS / Novartis AG - Depositary Receipt (Common Stock)

On May 6, 2026 - Atlantic Trust, LLC filed a 13F-HR form disclosing ownership of 550 shares of Novartis AG - Depositary Receipt (Common Stock) (US:NVS) valued at $84,012 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 696 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of -20.98% during the quarter. The current value of the position is $79,013 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F Novartis AG Spons ADR Com 66987V109 550 -146 -20.98 84 -11.58 0.0137
2026-02-09 2025-12-31 13F Novartis AG Spons ADR Com 66987V109 696 0 0.00 96 6.74 0.0151
2025-11-10 2025-09-30 13F Novartis AG Spons ADR Com 66987V109 696 -124 -15.12 89 -10.10 0.0152
2025-08-08 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 820 100 13.89 99 23.75 0.0188
2025-05-09 2025-03-31 13F Novartis AG Spons ADR Com 66987V109 720 200 38.46 80 60.00 0.0179
2025-02-10 2024-12-31 13F Novartis AG Spons ADR Com 66987V109 520 520 51 0.0109
2024-08-09 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 0 -269 -100.00 0 -100.00
2024-05-10 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 269 114 73.55 26 73.33 0.0068
2024-02-06 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 155 155 16 0.0043
2023-08-08 2023-06-30 13F Novartis AG Spon ADR COM 66987V109 0 -2,060 -100.00 0 -100.00
2023-05-10 2023-03-31 13F Novartis AG Spon ADR COM 66987V109 2,060 -15 -0.72 190 0.0605
2023-02-01 2022-12-31 13F Novartis AG Spon ADR COM 66987V109 2,075 -100 -4.60 0 -100.00 0.0630
2022-11-14 2022-09-30 13F NOVARTIS SPONSORED ADR 66987V109 2,175 100 4.82 166 -5.68 0.0578
2022-08-11 2022-06-30 13F Novartis AG Spon ADR COM 66987V109 2,075 0 0.00 176 -3.30 0.1339
2022-05-16 2022-03-31 13F Novartis AG Spon ADR COM 66987V109 2,075 0 0.00 182 0.00 0.1180
2022-02-09 2021-12-31 13F Novartis AG Spon ADR Com 66987V109 2,075 0 0.00 182 7.06 0.1074
2021-11-02 2021-09-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 170 -10.05 0.1077
2021-08-12 2021-06-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 189 6.78 0.1233
2021-04-30 2021-03-31 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 177 -9.69 0.1311
2021-02-16 2020-12-31 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 196 8.89 0.1165
2020-10-23 2020-09-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 180 -0.55 0.1430
2020-08-17 2020-06-30 13F Novartis AG Spon ADR Com 66987V109 2,075 0 0.00 181 5.85 0.1525
2020-05-12 2020-03-31 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 171 -12.76 0.1547
2020-02-03 2019-12-31 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 196 8.89 0.1436
2019-11-07 2019-09-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 180 -4.76 0.1403
2019-07-31 2019-06-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 189 -5.50 0.1509
2019-05-13 2019-03-31 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 200 12.36 0.1669
2019-02-13 2018-12-31 13F/A-1 Novartis AG ADR Com 66987V109 2,075 0 0.00 178 -0.56 0.1655
2019-02-13 2018-12-31 13F Novartis AG ADR Com 66987V109 2,075 178
2018-11-15 2018-09-30 13F Novartis AG ADR COM 66987V109 2,075 0 0.00 179 14.01 0.1373
2018-08-20 2018-06-30 13F Novartis AG ADR Com 66987V109 2,075 0 0.00 157 -6.55 0.1402
2018-05-15 2018-03-31 13F Novartis AG ADR COM 66987V109 2,075 0 0.00 168 -3.45 0.1442
2018-02-14 2017-12-31 13F Novartis AG ADR Com 66987V109 2,075 -8,765 -80.86 174 -81.31 0.1189
2017-11-17 2017-09-30 13F Novartis AG ADR Com 66987V109 10,840 0 0.00 931 3.56 0.6926
2017-08-21 2017-06-30 13F Novartis AG ADR Com 66987V109 10,840 0 0.00 899 11.68 0.7095
2017-06-19 2017-03-31 13F Novartis SPONSORED ADR 66987V109 10,840 0 0.00 805 0.75 0.6664
2017-06-14 2016-12-31 13F Novartis SPONSORED ADR 66987V109 10,840 10,840 799 0.7178
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.